Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Instituto do Cancer do Estado de São Paulo
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Sotio Biotech Inc.
Stanford University
FindCure Biosciences (ZhongShan) Co., Ltd.
Kaiser Permanente
University of Colorado, Denver
Eli Lilly and Company
Bayer
UNC Lineberger Comprehensive Cancer Center
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
UNC Lineberger Comprehensive Cancer Center
Washington University School of Medicine
Sensei Biotherapeutics, Inc.
Jonsson Comprehensive Cancer Center
Sichuan Enray Pharmaceutical Sciences Company
ModeX Therapeutics, An OPKO Health Company
University of Alabama at Birmingham
TransThera Sciences (Nanjing), Inc.
Columbia University
Theratechnologies
SOLTI Breast Cancer Research Group
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
Algemeen Ziekenhuis Maria Middelares
National Cancer Institute (NCI)
Universidade Federal de Pernambuco
Salubris Biotherapeutics Inc
NantCell, Inc.
TransThera Sciences (Nanjing), Inc.
Istituti Clinici Scientifici Maugeri SpA
M.D. Anderson Cancer Center
University Medical Center Groningen
Hoffmann-La Roche
Kineta Inc.
Institut Bergonié
Blue Note Therapeutics
MacroGenics
Lumos Pharma
Celgene
Zhujiang Hospital
Pfizer
Amgen
SWOG Cancer Research Network
University of Alabama at Birmingham